爱必妥联合放疗治疗中晚期食管癌临床观察及生活质量分析

【目的】评价爱必妥联合放疗治疗中晚期食管癌的临床疗效及对生活质量的影响。【方法】收集本院2006年1月-2007年8月期间接受放疗联合爱必妥治疗（联合治疗组）的初诊中晚期期食管癌25例,同期选取单纯放疗（单纯放疗组）患者25例进行对照。采用QLQ-C30调查表、OES-18于爱必妥使用前1d,放疗结束后1d、放疗结束后3个月调查患者的生存质量。【结果】联合治疗组有效率显著高于单纯放疗组（P〈0.05）。随访1、2年,疾病无进展生存率及总生存率联合治疗组均显著高于单纯放疗组（P〈0.05）。联合治疗组23/25例出现不同程度的痤疮样皮疹,而单纯放疗组未出现痤疮样皮疹改变,但放射性食管炎及肺炎在两组之间的发生率相似（P〉0.05）。放疗后1d及3个月联合治疗组患者吞咽困难、进食及梗阻的困扰显著小于单纯治疗组（P〈0.05）。【结论】爱必妥联合放疗治疗中晚期食管癌的近期疗效较好,并未出现毒副作用的累加和生活质量的下降,临床耐受性好。

Clinical effect and life quality of radiotherapy combined with Erbitux in the treatment of advanced esophageal carcinoma

Objectives] To evaluate the clinic effect of radiotherapy combined with Erbitux and its influence on the quality of life in the treatment of advanced esophageal carcinoma. Methods] A total of 25 advanced esophageal carcinoma patients of preliminary diagnosis receiving radiotherapy combined with Erbitux(combining group) were enrolled from January 2006 to August 2007 in our hospital, and another 25 patients receiving radiotherapy only(radiotherapy group) were selected as control during the corresponding tim...